Skip to main content
Top
Published in: Diabetologia 8/2019

01-08-2019 | Type 2 Diabetes | Article

Cellular circadian period length inversely correlates with HbA1c levels in individuals with type 2 diabetes

Authors: Flore Sinturel, Anne-Marie Makhlouf, Patrick Meyer, Christel Tran, Zoltan Pataky, Alain Golay, Guillaume Rey, Cédric Howald, Emmanouil T. Dermitzakis, Claude Pichard, Jacques Philippe, Steven A. Brown, Charna Dibner

Published in: Diabetologia | Issue 8/2019

Login to get access

Abstract

Aims/hypothesis

The circadian system plays an essential role in regulating the timing of human metabolism. Indeed, circadian misalignment is strongly associated with high rates of metabolic disorders. The properties of the circadian oscillator can be measured in cells cultured in vitro and these cellular rhythms are highly informative of the physiological circadian rhythm in vivo. We aimed to discover whether molecular properties of the circadian oscillator are altered as a result of type 2 diabetes.

Methods

We assessed molecular clock properties in dermal fibroblasts established from skin biopsies taken from nine obese and eight non-obese individuals with type 2 diabetes and 11 non-diabetic control individuals. Following in vitro synchronisation, primary fibroblast cultures were subjected to continuous assessment of circadian bioluminescence profiles based on lentiviral luciferase reporters.

Results

We observed a significant inverse correlation (ρ = −0.592; p < 0.05) between HbA1c values and circadian period length within cells from the type 2 diabetes group. RNA sequencing analysis conducted on samples from this group revealed that ICAM1, encoding the endothelial adhesion protein, was differentially expressed in fibroblasts from individuals with poorly controlled vs well-controlled type 2 diabetes and its levels correlated with cellular period length. Consistent with this circadian link, the ICAM1 gene also displayed rhythmic binding of the circadian locomotor output cycles kaput (CLOCK) protein that correlated with gene expression.

Conclusions/interpretation

We provide for the first time a potential molecular link between glycaemic control in individuals with type 2 diabetes and circadian clock machinery. This paves the way for further mechanistic understanding of circadian oscillator changes upon type 2 diabetes development in humans.

Data availability

RNA sequencing data and clinical phenotypic data have been deposited at the European Genome-phenome Archive (EGA), which is hosted by the European Bioinformatics Institute (EBI) and the Centre for Genomic Regulation (CRG), ega-box-1210, under accession no. EGAS00001003622.
Appendix
Available only for authorised users
Literature
13.
go back to reference Saini C, Brown SA, Dibner C (2015) Human peripheral clocks: applications for studying circadian phenotypes in physiology and pathophysiology. Front Neurol 6:95PubMedPubMedCentral Saini C, Brown SA, Dibner C (2015) Human peripheral clocks: applications for studying circadian phenotypes in physiology and pathophysiology. Front Neurol 6:95PubMedPubMedCentral
18.
go back to reference Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 57(1):289–300 Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 57(1):289–300
Metadata
Title
Cellular circadian period length inversely correlates with HbA1c levels in individuals with type 2 diabetes
Authors
Flore Sinturel
Anne-Marie Makhlouf
Patrick Meyer
Christel Tran
Zoltan Pataky
Alain Golay
Guillaume Rey
Cédric Howald
Emmanouil T. Dermitzakis
Claude Pichard
Jacques Philippe
Steven A. Brown
Charna Dibner
Publication date
01-08-2019
Publisher
Springer Berlin Heidelberg
Keyword
Type 2 Diabetes
Published in
Diabetologia / Issue 8/2019
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-019-4907-0

Other articles of this Issue 8/2019

Diabetologia 8/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.